RNXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RenovoRx Inc (RNXT) is not a strong buy at the moment for a beginner, long-term investor. The stock lacks clear positive trading signals, has bearish technical indicators, and its financial performance shows limited growth with ongoing losses. While the company's innovative medical technology and FDA-cleared device present potential, the current pre-market price trend and lack of strong catalysts suggest waiting for more favorable conditions.
The technical indicators are bearish. The MACD is negatively expanding below 0, RSI is neutral at 36.678, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The pre-market price is $0.9206, down 1.03%, and it is trading below the pivot level of $0.994, with support at $0.933 and $0.895.
RenovoRx has formed a Medical Advisory Board to enhance oncology strategies, and its FDA-cleared RenovoCath device is seen as particularly useful for treating pancreatic cancer. Analyst Justin Walsh has initiated coverage with a Buy rating and an $8 price target.
The stock is trading in a bearish trend with no significant hedge fund or insider trading activity. Financial performance shows ongoing losses with a net income of -$2.91M in Q3 2025, and EPS dropped by 20% YoY. The pre-market price is down 1.03%, and there is no recent congress trading data or strong trading signals.
In Q3 2025, revenue remained flat at $266,000 YoY. Net income improved by 17.85% YoY but remains negative at -$2.91M. EPS dropped by 20% YoY to -0.08, and gross margin stayed flat at 80.08%. Overall, the company is not yet profitable.
Analyst Justin Walsh from JonesResearch initiated coverage with a Buy rating and an $8 price target, citing the potential of RenovoCath for treating pancreatic cancer. However, no recent updates or changes in analyst ratings have been noted.
